In this light, we described the loss of KRAS pathogenic mutations from primary to metastatic tumors in a well-defined model of lung-specific oligometastatic disease, allowing a clean genotype/phenotype correlation study (3). The gene discussed is KRAS; the disease is metastatic neoplasm.